Skip to main content

CRO India for Asia-Pacific Sponsors

  • Home
  • CRO India for Asia-Pacific Sponsors

Clinical research, regulatory and compliance information from BioAgile Therapeutics.

Need Expert Help? We’re Just a Call Away.

In short: Sponsors in Australia and Malaysia can run clinical studies in India and use them alongside local approvals in their own market. Each country has its own notification or licensing step, and its own ethics committee requirement. BioAgile Therapeutics is a CDSCO-approved, ISO 9001:2015 certified CRO with headquarters in Bengaluru. We manage the Indian part of the study and plan it around the filing you have to make at home.

Two markets, two different systems

MarketRegulatorWhat the regulator says
AustraliaTGA, CTN schemeThe Australian trial sponsor submits a Clinical Trial Notification (CTN) and pays the fee. The TGA does not evaluate trial data at notification. Approval from a Human Research Ethics Committee (HREC) and from the institution where the trial is carried out is also needed.
MalaysiaNPRA, CTIL and CTXFor a trial with products that need a Clinical Trial Import Licence (CTIL) or Clinical Trial Exemption (CTX), the trial cannot start until an ethics committee gives a favourable opinion and NPRA approves the application.

Australia: what to plan for

Under the TGA’s CTN scheme, the trial is notified by an Australian clinical trial sponsor. The TGA says it does not evaluate data about the trial at notification, so the scientific and ethical review happens through the HREC. A trial cannot supply the unapproved product until the CTN has been submitted and the fee paid, and the sponsor must have the HREC and institution approvals in place. The TGA also publishes an Australian clinical trial handbook that sets out the sponsor’s responsibilities.

If part of your programme runs in India, the Indian protocol, consent forms and safety reporting should match what your Australian HREC reviews. We prepare those documents once and plan the Indian approvals in parallel, so the two timelines do not hold each other up.

Malaysia: what to plan for

NPRA’s guideline says that for products needing a CTIL or CTX, the trial cannot commence until the ethics committee issues a favourable opinion and NPRA approves the application. It also says that, following a WHO regulatory system assessment in November 2023, a CTIL or CTX is now issued for each product and protocol and cannot be shared between trials, for new applications. Clinical trials needing a CTIL or CTX must also be registered on the National Medical Research Register (NMRR), and the NMRR ID is needed for the approval. NPRA states that sponsors, investigators, sites and CROs involved in trials in Malaysia must follow the Malaysian Guideline for Good Clinical Practice.

For a programme that includes India, we line up the Indian submissions with your Malaysian filing so that the protocol version is the same in both.

What BioAgile handles in India

Indian approvals

CDSCO permission and ethics committee approval under the New Drugs and Clinical Trials Rules, 2019, plus CTRI registration. See regulatory support.

Study conduct

Site selection, monitoring, safety reporting and project management. See clinical trials and BA/BE studies.

Data and statistics

Data management and biostatistics to a plan agreed before enrolment. See data management and biostatistics.

Reports and quality

Protocols and clinical study reports in ICH structure, and audit-ready records. See medical writing and quality assurance.

Our overview of the Indian framework is on the CRO in India page. For the US and Europe, see CRO India for US sponsors and CRO India for European sponsors. BioAgile holds CDSCO registration as a CRO (Reg. No. CRO/KA/2026/000173) and ISO 9001:2015 certification.

Working across time zones

India is 2.5 hours behind Malaysia, so Indian office hours (9:30 am to 6:00 pm IST) are noon to 8:30 pm there and most of the Malaysian working day is covered. Eastern Australia is 4.5 hours ahead of India in standard time and 5.5 hours ahead in daylight saving time, so the overlap with Australian working hours is shorter, and calls are best scheduled in the Australian afternoon. We agree a call schedule and a named project manager at kick-off.

Frequently asked questions

Do I need a CTN in Australia if the study runs in India?

The CTN is a notification made by the Australian trial sponsor for trials in Australia using an unapproved product. Whether it applies to your programme depends on where the trial sites are. Check this with your Australian regulatory adviser. We run the Indian part and align the documents.

Does the TGA review the trial data when a CTN is submitted?

No. The TGA states that it does not evaluate any data about the trial at the time of notification. The HREC reviews the trial.

When can a Malaysian trial start?

For products that need a CTIL or CTX, the trial cannot commence until the ethics committee gives a favourable opinion and NPRA approves the application.

Does BioAgile handle the Indian regulatory submissions?

Yes. We handle CDSCO submissions, ethics committee approvals and CTRI registration for the India part of your study.

Official sources

Planning an India study for an Asia-Pacific programme?

Tell us the product, the study type and the market you are filing in. We will reply with a plan for the India side and the questions we need answered.

Contact our teamCall 080 4375 4520